Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05433753
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
Sponsor: National Cancer Center, Japan
View on ClinicalTrials.gov
Summary
This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
Official title: Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy; HARMONY Study
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2022-05-24
Completion Date
2027-09-30
Last Updated
2024-03-25
Healthy Volunteers
No
Conditions
Locations (1)
National Cancer Center Hospital, Japan
Chuo-ku, Tokyo, Japan